(NASDAQ: RXRX) Recursion Pharmaceuticals's forecast annual revenue growth rate of 21.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.34%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Recursion Pharmaceuticals's revenue in 2024 is $46,235,000.On average, 5 Wall Street analysts forecast RXRX's revenue for 2024 to be $10,930,627,419, with the lowest RXRX revenue forecast at $1,600,189,477, and the highest RXRX revenue forecast at $19,797,383,544. On average, 5 Wall Street analysts forecast RXRX's revenue for 2025 to be $13,137,096,912, with the lowest RXRX revenue forecast at $3,034,965,040, and the highest RXRX revenue forecast at $20,819,337,317.
In 2026, RXRX is forecast to generate $27,177,791,090 in revenue, with the lowest revenue forecast at $4,826,711,433 and the highest revenue forecast at $49,529,108,411.